Neuropathic Pain-Drug Pipeline Analysis and Market Forecasts to 2015

Oct. 8, 2010 - PRLog -- "Neuropathic Pain-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis.
Global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products.

There are over 111 molecules in various stages of the pipeline. Vimpat, Qutenza, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war.

Scope
The scope of the report includes:
-Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists,  TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.
-Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc., AstraZeneca.  
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global neuropathic pain market landscape? -Identify, understand and capitalize.



Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Global Melanoma Market: Market Characterization
2.1 Overview
2.2 Melanoma Market Size
2.3 Melanoma Market Forecast and Compound Annual Growth Rate
2.4 Drivers and Barriers for the Melanoma Market
2.4.1 Drivers for the Melanoma Market
2.4.2 Barriers for the Melanoma Market
2.5 Key Takeaway
3 Global Melanoma Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Melanoma Market
3.3.1 DTIC-Dome (Dacarbazine)
3.3.2 Proleukin (Aldesleukin)
3.3.3 Intro A (interferon alpha 2b)
3.4 Key Take Away
4 Global Melanoma Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.3 Melanoma Market-Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 PegIntron (Pegylated interferon alfa-2b)
4.4.2 Multiferon (Human Albumin)
4.4.3 Oncovex GMCSF (HSV DNA Vaccine)
4.4.4 Ipilimumab (MDX-010, MDX-101)
4.4.5 Allovectin-7
4.5 Melanoma Market-Clinical Pipeline by Mechanism of Action
4.5.1 Melanoma Market-Phase III Clinical Pipeline
4.5.2 Melanoma Market-Phase II Clinical Pipeline
4.5.3 Melanoma Market-Phase I Clinical Pipeline
4.5.4 Melanoma Market-Preclinical Pipeline
4.5.5 Melanoma Market-Discovery Phase Pipeline
4.5.6 Melanoma Market-List of Terminated Clinical Trials
4.6 Key Takeaway
5 Global Melanoma Market: Implications for Future Market Competition
6 Global Melanoma Market: Future Players in Melanoma Market
6.1 Introduction
6.2 Abraxis BioScience
6.2.1 Company Overview
6.2.2 Business Description
6.3 GlaxoSmithKline
6.3.1 Overview
6.3.2 Business Description
6.4 Schering-Plough
6.4.1 Overview
6.4.2 Business Description
6.5 Genta Incorporated
6.5.1 Overview
6.5.2 Business Description
6.6 Swedish Orphan International AB
6.6.1 Overview
6.7 Bristol-Myers Squibb
6.7.1 Overview
6.7.2 Business Description
6.8 Bayer Schering Pharma AG
6.8.1 Overview
6.8.2 Business Description
6.9 Oncolytics Biotech
6.9.1 Introduction
6.9.2 Business Discription
7 Melanoma Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Tables
Table 1: Global Neuropathic Pain Therapeutics Market, Revenue Forecasts ($m), 2006-2015
Table 2: Major Marketed Products Comparison in the Neuropathic Pain  Market, 2009
Table 3: Neuropathic Pain Therapeutics-Most Promising Drugs under Clinical Development, 2009
Table 4: Neuropathic Pain Therapeutics-Regulatory Filing and Phase III Clinical Pipeline, 2009
……

List of Figures
Figure 1: Global Neuropathic Pain Market Forecast 2006-2015
Figure 2: Opportunity and Unmet Need in the Neuropathic Pain Market, 2009
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Neuropathic Pain, 2009
……

# # #

ChinaCCM.com is China's leading industry consultancy expert offering industry intelligence and research solution, ChinaCCM Market Research Centre is a research division focusing on professional market survey and industry research.